Skip to main content
Fig. 3 | Diagnostic Pathology

Fig. 3

From: PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway

Fig. 3

PAK4 knockdown inhibits the cisplatin resistance in cervical cancer cells. a: PAK4 mRNA level in Hela cells which were transfected with the PAK4-targeted siRNA (siRNA-PAK4) or with the control siRNA (siRNA-Con) with a concentration of 25 or 50 nM; b: Western blot analysis of PAK4 in protein level in the siRNA-PAK4- or siRNA-Con-transfected Hela cells; C and D: Influence of the transfection with siRNA-PAK4 or with siRNA-Con on the viability of Hela (c) and CaSki (d) cells, post the treatment with5 μM (for Hela cells) or 10 μM (for CaSki cells) cisplatin for 12, 24 or 48 h. Each value was averaged for triple independent results. *P < 0.05, **P < 0.01 or ***P < 0.001, ns: no significance

Back to article page